Nectero Therapeutics recently released two-year outcomes data from the company’s first-in-human (FIH) trial of their investigational Nectero Endovascular Aneurysm Stabilisation Treatment (EAST) system. The results were presented by Andrew Holden (Auckland City Hospital, Auckland, New Zealand) at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK).
The therapy, developed by Nectero, is intended to treat patients with small- to medium-sized aneurysms earlier in the abdominal aortic aneurysm (AAA) disease process, with the potential to delay or avoid higher-risk endograft or open repair procedures. The investigational drug, containing the active pharmaceutical ingredient pentagalloylglucose (PGG), is administered as a single treatment delivered locally into the aneurysmal wall with a dual-balloon delivery catheter.
The FIH study enrolled 46 patients with aneurysms of a median maximum diameter of 4.3cm. Average patient age was 70 years, 89% were male and average body mass index (BMI) was 27kg/m2. The average procedure time was less than 45 minutes, with sites reporting 100% technical success in delivering the therapy. There were no major adverse events through 30 days, nor any treatment-related adverse events reported after 30 days.
Through two-year follow-up, investigators measured a median aneurysm diameter growth of 1mm per year. A press release notes that this represents a significant reduction in the expected AAA growth rate, with nearly 90% of the aneurysms growing less than expected compared to what’s been historically documented and published. Additionally, the AAA proximal neck diameters remained stable, with no dilatation, in the one-year preliminary analysis.
Holden summarised: “Through two-year follow-up in this FIH trial, it’s been shown that a single, local dose of PGG in patients with small- to medium-sized abdominal aortic aneurysms demonstrates an acceptable safety profile with a profound impact on reducing AAA growth. Additionally, we’ve seen a positive, early clinical signal towards proximal neck stabilisation.”
Nectero advises that a full two-year analysis on AAA proximal neck diameters will be released during a late-breaking session at the upcoming Vascular Annual Meeting (VAM; 10–13 June, Boston, USA) and three-year follow-up from the FIH trial will be completed by the end of 2026.
